213 related articles for article (PubMed ID: 32379269)
1. Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial.
Navari RM; Pywell CM; Le-Rademacher JG; White P; Dodge AB; Albany C; Loprinzi CL
JAMA Oncol; 2020 Jun; 6(6):895-899. PubMed ID: 32379269
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
[TBL] [Abstract][Full Text] [Related]
3. Patient-perceived symptomatic benefits of olanzapine treatment for nausea and vomiting in patients with advanced cancer who received palliative care through consultation teams: a multicenter prospective observational study.
Maeda I; Satomi E; Kiuchi D; Nishijima K; Matsuda Y; Tokoro A; Tagami K; Matsumoto Y; Naito A; Morita T; Iwase S; ; Otani H; Odagiri T; Watanabe H; Mori M; Matsuda Y; Nagaoka H; Mayuzumi M; Kanai Y; Sakamoto N; Ariyoshi K
Support Care Cancer; 2021 Oct; 29(10):5831-5838. PubMed ID: 33742244
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy: A Secondary Analysis of the J-FORCE Randomized Clinical Trial.
Abe M; Yamaguchi T; Fujita Y; Nishimura T; Kitagawa K; Inui N; Hirano K; Sakata Y; Iihara H; Shibuya Y; Suzuki K; Shibata K; Hori K; Daga H; Nakayama T; Sakata Y; Takahashi TY; Zenda S; Hashimoto H
JAMA Netw Open; 2023 May; 6(5):e2310894. PubMed ID: 37129897
[TBL] [Abstract][Full Text] [Related]
5. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study.
Mizukami N; Yamauchi M; Koike K; Watanabe A; Ichihara K; Masumori N; Yamakage M
J Pain Symptom Manage; 2014 Mar; 47(3):542-50. PubMed ID: 23856100
[TBL] [Abstract][Full Text] [Related]
6. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
[TBL] [Abstract][Full Text] [Related]
7. Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study.
Mukhopadhyay S; Dutta P; Banerjee S; Bhattacharya B; Biswas S; M Navari R
Future Oncol; 2021 Jun; 17(16):2041-2056. PubMed ID: 33792376
[TBL] [Abstract][Full Text] [Related]
8. Ondansetron and metoclopramide as second-line antiemetics in women with nausea and vomiting in pregnancy: the EMPOWER pilot factorial RCT.
Robson S; McParlin C; Mossop H; Lie M; Fernandez-Garcia C; Howel D; Graham R; Ternent L; Steel A; Goudie N; Nadeem A; Phillipson J; Shehmar M; Simpson N; Tuffnell D; Campbell I; Williams R; O'Hara ME; McColl E; Nelson-Piercy C
Health Technol Assess; 2021 Nov; 25(63):1-116. PubMed ID: 34782054
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine for prevention of chemotherapy-induced nausea and vomiting in children and adolescents: a multi-center, feasibility study.
Flank J; Schechter T; Gibson P; Johnston DL; Orsey AD; Portwine C; Sung L; Dupuis LL
Support Care Cancer; 2018 Feb; 26(2):549-555. PubMed ID: 28856448
[TBL] [Abstract][Full Text] [Related]
10. Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B).
Sakai H; Tsurutani J; Ozaki Y; Ishiguro H; Nozawa K; Watanabe K; Maeda S; Yokoe T; Imamura CK; Matsumoto K; Iwasa T; Chiba Y; Takiguchi D; Takano T
BMJ Open; 2023 Apr; 13(4):e070304. PubMed ID: 37012013
[TBL] [Abstract][Full Text] [Related]
11. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Navari RM; Nagy CK; Gray SE
Support Care Cancer; 2013 Jun; 21(6):1655-63. PubMed ID: 23314603
[TBL] [Abstract][Full Text] [Related]
12. Effects of 5-mg dose of olanzapine for breakthrough nausea and vomiting in patients receiving carboplatin-based chemotherapy: a prospective trial.
Maeda A; Yoshida H; Inoue H; Ejiri M; Yamaguchi S; Kushihara H; Yamamoto Y; Ando Y; Sato Y; Tashiro Y; Hasegawa A; Takahara Y; Mizutani M; Oze I; Shimizu J
Ann Palliat Med; 2021 Mar; 10(3):2699-2708. PubMed ID: 33615803
[TBL] [Abstract][Full Text] [Related]
13. Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy.
Slimano F; Netzer F; Borget I; Lemare F; Besse B
Int J Clin Pharm; 2018 Oct; 40(5):1265-1271. PubMed ID: 29744791
[TBL] [Abstract][Full Text] [Related]
14. A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients.
Yeo W; Lau TK; Li L; Lai KT; Pang E; Cheung M; Chan VT; Wong A; Soo WM; Yeung VT; Tse T; Lam DC; Yeung EW; Ng KP; Tang NL; Tong M; Suen JJ; Mo FK
Breast; 2020 Apr; 50():30-38. PubMed ID: 31978815
[TBL] [Abstract][Full Text] [Related]
15. Olanzapine for the Prevention of Postdischarge Nausea and Vomiting after Ambulatory Surgery: A Randomized Controlled Trial.
Hyman JB; Park C; Lin HM; Cole B; Rosen L; Fenske SS; Barr Grzesh RL; Blank SV; Polsky SB; Hartnett M; Taub PJ; Palvia V; DeMaria S; Ascher-Walsh C
Anesthesiology; 2020 Jun; 132(6):1419-1428. PubMed ID: 32229754
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Vimolchalao V; Sakdejayont S; Wongchanapai P; Sukprakun S; Angspatt P; Thawinwisan W; Chenaksara P; Sriuranpong V; Vinayanuwatikun C; Parinyanitikun N; Poovorawan N; Tanasanvimon S
Int J Clin Oncol; 2020 Feb; 25(2):396-402. PubMed ID: 31776732
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting.
Clemons M; Dranitsaris G; Sienkiewicz M; Sehdev S; Ng T; Robinson A; Mates M; Hsu T; McGee S; Freedman O; Kumar V; Fergusson D; Hutton B; Vandermeer L; Hilton J
Breast; 2020 Dec; 54():278-285. PubMed ID: 33242754
[TBL] [Abstract][Full Text] [Related]
18. The effectiveness and cost-effectiveness of acupressure for the control and management of chemotherapy-related acute and delayed nausea: Assessment of Nausea in Chemotherapy Research (ANCHoR), a randomised controlled trial.
Molassiotis A; Russell W; Hughes J; Breckons M; Lloyd-Williams M; Richardson J; Hulme C; Brearley S; Campbell M; Garrow A; Ryder W
Health Technol Assess; 2013 Jun; 17(26):1-114. PubMed ID: 23803562
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis.
Yang T; Liu Q; Lu M; Ma L; Zhou Y; Cui Y
Br J Clin Pharmacol; 2017 Jul; 83(7):1369-1379. PubMed ID: 28112422
[TBL] [Abstract][Full Text] [Related]
20. Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study.
Harder S; Groenvold M; Isaksen J; Sigaard J; Frandsen KB; Neergaard MA; Mondrup L; Herrstedt J
Support Care Cancer; 2019 Aug; 27(8):2849-2856. PubMed ID: 30552594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
